EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary-Reference-Cited by-同舟云学术

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary

Published:2024-06-13 Issue: Volume: Page:
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

, ,

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00125-024-06196-3.pdf

Reference8 articles.

1. Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399(10319):61–116. https://doi.org/10.1016/S0140-6736(21)01701-3

2. Rinella ME, Lazarus JV, Ratziu V et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79(6):1542–56. https://doi.org/10.1016/j.jhep.2023.06.003

3. European Association for the Study of the Liver (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004

4. Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L (2024) Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. https://doi.org/10.1016/j.jhep.2024.01.014

5. OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. 2011. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence. Accessed 27 Jan 2023